Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study.

Authors:
Address: Hospital das Clínicas, São Paulo, Brazil.
Journal:

Publication:

abstract

BACKGROUND:

Yellow fever (YF) may be very serious, with mortality reaching 50%. Live attenuated virus YF vaccine (YFV) is effective, but may present, although rare, life-threatening side effects and is contraindicated in immunocompromised patients. However, some transplant patients may inadvertently receive the vaccine.

METHODS:

A questionnaire was sent to all associated doctors to the Brazilian organ Transplantation Association through its website, calling for reports of organ transplanted patients who have been vaccinated against YF.

RESULTS:

Twelve doctors reported 19 cases. None had important side effects. Only one had slight reaction at the site of YFV injection. Eleven patients were male. Organs received were 14 kidneys, 3 hearts, and 2 livers. Twelve patients received organs from deceased donors. Mean age at YFV was 45.6 ± 13.6 years old (range 11-69); creatinine: 1.46 ± 0.62 mg/dL (range 0.8-3.4); post-transplant time: 65 ± 83.9 months (range 3-340); and time from YFV at the time of survey: 45 ± 51 months (range 3-241). Immunosuppression varied widely with different drug combinations: azathioprine (7 patients), cyclosporine (8), deflazacort (1), mycophenolate (10), prednisone (11), sirolimus (3), and tacrolimus (4).

CONCLUSIONS:

YFV showed no important side effects in this cohort of solid organ transplanted patients. However, owing to the small number of studied patients, it is not possible to extend these findings to the rest of the transplanted population, assuring safety. Therefore, these data are not strong enough to safely recommend YFV in organ transplanted recipients, as severe, even life-threatening side effects may occur.

Related Articles
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program. Rep Carcinog Backgr Doc. 2010 Jan; (10-5981):i-512.
[Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
Kansenshogaku Zasshi. 2002
[Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
Taga K, Imura S, Hayashi A, Kamakura K, Hashimoto S, Takasaki T, Kurane I, Uchida Y. Kansenshogaku Zasshi. 2002 Sep; 76(9):738-46.
Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2010
Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2010 Jul 30; 59(RR-7):1-27.
Review A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Health Technol Assess. 2006
Review A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS. Health Technol Assess. 2006 Dec; 10(49):iii-iv, ix-xi, 1-157.
Review Yellow fever vaccine: past, present and future.
Expert Opin Biol Ther. 2008
Review Yellow fever vaccine: past, present and future.
Roukens AH, Visser LG. Expert Opin Biol Ther. 2008 Nov; 8(11):1787-95.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.